Αποτελέσματα Αναζήτησης
Median overall survival was 9.9 years (95% confidence interval [95% CI] 7.9–11.9). Patients without recurrence experienced longer median survival (not reached) than patients with one or more recurrences (8.92 years) (p < 0.001) and had a high rate (48.8%) of MGMT promoter-unmethylated tumours.
Wild-type isocitrate dehydrogenase glioblastoma (IDH wt GBM) is the most common primary malignant brain cancer and accounts for ≥90% of all adult GBM diagnoses. Patients with IDH wt GBM have a median age of diagnosis at 68–70 years of age, and increasing age is associated with an increasingly worse prognosis for patients with this type of GBM.
24 Οκτ 2023 · The classification estimates median survival in three subgroups: RPA class III (age < 50 years, KPS ≥ 90), 17.1 months (12-month survival 70%); RPA class IV (age <50, KPS <90), 11.2 months (12-month survival 46%); and RPA class V (all others), 7.5 months (12-month survival 28%).
However, in patients over age 70, survival was significantly improved with hypofractionated RT ... Mutations in IDH and the glioma CpG island methylator phenotype are much less ... Kruchko C., Barnholtz-Sloan J.S. Glioblastoma incidence rate trends in Canada and the United States compared with England, 1995–2015. Neuro-oncology. 2020;22:301 ...
15 Μαρ 2023 · Sixteen patients were long-term survivors. Age < 70 years, MGMT promoter methylation, extent of resection ≥ 95%, and administration of radiochemotherapy were associated with LTS (P = 0.005, P < 0.001, P = 0.048, and P = 0.008, respectively).
Median survival is only 14-16 months after diagnosis, with patients aged ≥ 65 years reportedly showing worse outcome. This study aimed to further evaluate the prognostic role of age in a homogenously treated patient cohort.
1 Ιουν 2020 · Overall, the prognosis for patients with this disease is poor, with a median survival of <2 years. There is a slight predominance in males, and incidence increases with age. The standard approach to therapy in the newly diagnosed setting includes surgery followed by concurrent radiotherapy with temozolomide and further adjuvant temozolomide.
